Literature DB >> 16525829

Vasculitis treatment - new therapeutic approaches.

Michael J Dillon1.   

Abstract

In childhood, vasculitis carries with it a not inconsequential morbidity and mortality. Current therapy is usually effective in inducing remission, but there is a penalty in terms of significant and serious side effects as well as concerns about long-term maintenance regimens. Additionally, some patients are recalcitrant to treatment and options have, hitherto, been limited in relation to alternative therapy. In view of this, novel therapeutic approaches are being explored that include the better use of long-established agents as well as the utilization of newer immunosuppressive and immunomodulatory strategies. Blockade of circulating mediators and surface receptors as well as lymphocyte depletion and immunoablation are being introduced predominantly in adults but increasingly also in children. With greater understanding of the pathogenetic mechanisms involved in the disease processes it is becoming possible to utilize much more focussed therapy for these serious and life-threatening disorders with, hopefully, a decrease in long-term morbidity and mortality as well as a diminution of drug-induced adverse effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525829     DOI: 10.1007/s00431-005-0070-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  82 in total

Review 1.  [Immunomodulatory effects of intravenous immunoglobulins].

Authors:  M Kazatchkine; L Mouthon; S V Kaveri
Journal:  Ann Med Interne (Paris)       Date:  2000-05

Review 2.  What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides.

Authors:  K de Groot; D Jayne
Journal:  Clin Nephrol       Date:  2005-12       Impact factor: 0.975

3.  Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.

Authors:  C M Lockwood; S Thiru; S Stewart; G Hale; J Isaacs; P Wraight; J Elliott; H Waldmann
Journal:  QJM       Date:  1996-12

4.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Authors:  D R Jayne; H Chapel; D Adu; S Misbah; D O'Donoghue; D Scott; C M Lockwood
Journal:  QJM       Date:  2000-07

5.  Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.

Authors:  M Gayraud; L Guillevin; P le Toumelin; P Cohen; F Lhote; P Casassus; B Jarrousse
Journal:  Arthritis Rheum       Date:  2001-03

6.  Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin.

Authors:  R C Dale; M A Saleem; S Daw; M J Dillon
Journal:  J Pediatr       Date:  2000-11       Impact factor: 4.406

7.  Effective B cell depletion with rituximab in the treatment of autoimmune diseases.

Authors:  Christian Kneitz; Martin Wilhelm; Hans Peter Tony
Journal:  Immunobiology       Date:  2002-12       Impact factor: 3.144

8.  [Induction of remission with infliximab in therapy-refractory Wegener's granulomatosis - Follow-up of six patients].

Authors:  P Lamprecht; O Arbach; J Voswinkel; T Lilienthal; B Nölle; M Heller; A Gause; W L Gross
Journal:  Dtsch Med Wochenschr       Date:  2002-09-13       Impact factor: 0.628

9.  Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.

Authors:  Gary S Hoffman; Peter A Merkel; Richard D Brasington; Deborah J Lenschow; Patrick Liang
Journal:  Arthritis Rheum       Date:  2004-07

10.  Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients.

Authors:  L Guillevin; O Fain; F Lhote; B Jarrousse; D Le Thi Huong; A Bussel; A Leon
Journal:  Arthritis Rheum       Date:  1992-02
View more
  5 in total

Review 1.  Pediatric vasculitis.

Authors:  Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

2.  Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs.

Authors:  Falcini Fernanda; Capannini Serena; Russo Giustina; Battagliese Antonella; D'Amico Alessandra; Maria Alessio; Alessio Maria
Journal:  Rheumatol Int       Date:  2011-07-24       Impact factor: 3.580

Review 3.  Small vessel vasculitis.

Authors:  Paul Brogan; Despina Eleftheriou; Michael Dillon
Journal:  Pediatr Nephrol       Date:  2009-11-03       Impact factor: 3.714

Review 4.  Medium-size-vessel vasculitis.

Authors:  Michael J Dillon; Despina Eleftheriou; Paul A Brogan
Journal:  Pediatr Nephrol       Date:  2009-11-28       Impact factor: 3.714

Review 5.  Vasculitis in children.

Authors:  Despina Eleftheriou; Paul A Brogan
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-06       Impact factor: 4.098

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.